---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096362"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:48:27.777900+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July

## Summary
- Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.
- First commercial sales of QUELIMMUNE for pediatric AKI in July 2024; launched with U.S. distribution partner.
- Adult NEUTRALIZE-AKI trial enrolled 42 subjects at 9 sites; CMS granted Category B coverage for Medicare/Medicaid.
- Completed $10M registered direct offering in July; cash ~$6.9M as of July 31 after reducing debt by $2.7M.
- Board expanded with three new directors; expects adult PMA approval in H1 2026.

## SEC filing metadata
- accession: 0000950170-24-096362
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/0000950170-24-096362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/icu-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096362
- JSON: https://secwatch.observer/filing/0000950170-24-096362.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.